The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
New research shows that patients receiving mismatched unrelated donor stem cell transplants achieve similar survival rates, regardless of HLA matching levels.
The treatment combination was previously approved in BRCA2m-positive patients with metastatic castrate-resistant prostate cancer.
Pharmaceutical Technology on MSN
FDA approves Acadia’s Daybue Stix for Rett syndrome
The US Food and Drug Administration (FDA) has granted approval for Acadia Pharmaceuticals’ Daybue Stix (trofinetide).
本期看点：1. 抗半乳糖凝集素-9（galectin-9）单克隆抗体LYT-200用于治疗复发/难治性急性髓系白血病（AML）和高风险骨髓增生异常综合征（MDS），在一项早期临床试验中联合标准疗法，使患者的初步总生存期（OS）较同类患者延长近10个月。2.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈